Proof of concept of NX‐2127, a first‐in‐class Bruton's Tyrosine Kinase (BTK) dual‐targeted protein degrader with immunomodulatory activity, in patients with DLBCL
Alexey V. Danilov(City of Hope), Adrian Wiestner(National Institutes of Health), Weiyun Z. Ai(City College of San Francisco), A. Schwab(Erasmus MC), Clare Sun(National Heart Lung and Blood Institute), Michael Wang(St. Joseph Health System), Philip O’Connor(Leeds General Infirmary), M. Tan(Nurix (United States)), Krish Patel
Cited by 0
Related Papers
KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma
|New England Journal of Medicine|2020|1.9k
Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma
|New England Journal of Medicine|2013|1.7k
Printability and Shape Fidelity of Bioinks in 3D Bioprinting
|Chemical Reviews|2020|1.2k
A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma
|Proceedings of the National Academy of Sciences|2003|1k